The World Gastrointestinal Disorders Market 2006-2011

The purpose of this visiongain report is to examine the prospects of the world gastrointestinal market. The gastrointestinal (GI) disorders market is one of the largest and most important in the pharmaceutical industry, generating revenues of over $16 billion in 2004. This report examines the GI market critically through a comprehensive review of available information, including that from commercial databases, consultation with the industry, company reports, business/industry news and consultation with international experts on GI disorders. Visiongain applied techniques such as financial forecasting, SWOT analysis and the assessment of unmet needs to provide a comprehensive market report with detailed analyses and informed opinion.

In particular, this report concentrates on the following essential aspects of the GI market:

> The current state of the world market for drugs to treat gastrointestinal disorders

> Drivers and opportunities in the GI market

> Restraints and threats in the GI market

> Revenue trends in the world gastrointestinal market between 2005-2011

> Prospects for the leading GI drugs between 2005-2011

> A comprehensive discussion of patent expiry and generic substitution

> An assessment of prescription-to-OTC switching and lifecycle management

> A breakdown of the world GI market into the principal geographical regions, with estimates of potential treatment populations and forecasted revenues to 2011

> An analysis of unmet needs in the GI market, with discussion of potential solutions

> A discussion of pricing, with comparisons between leading products and substitutes

> A discussion of DTC advertising with emphasis on issues and strategies

> Detailed information on pipeline products, with an analysis of the prospects for these agents

Why you should buy this report

> To receive a comprehensive analysis of the prospects of the world gastrointestinal market from 2005-2011

> To find out predicted revenues, growth rates and market shares for all the leading GI drugs from 2005-2011

> To determine the forces that influence the gastrointestinal market, especially:

- Competitive characteristics

- Drivers and restraints

- Strengths, weaknesses, opportunities and threats

- Unmet needs according to world experts, with gaps in the market exposed

> To find out the prospects for GI drugs in the leading geographical markets:

- Potential treatment populations

- Potential 2011 revenues in the leading 7 markets

> To find out about pipeline developments for treating GI disorders

Organisations Listed:

Abbott Laboratories

Adolor Corp

Alizyme

Altana

Andrx Pharma

Apotex Corporation

Astellas Pharma

AstraZeneca

Axcan Pharma

Bentley Pharmaceuticals

Berlex Inc

Bristol-Myers Squibb

Centocor Inc

Consilient Health

CyberPharm Investment Co

Daewoong Pharmaceutical Co

Dainippon Pharmaceutical

Dainippon Sumitomo Pharma Co

Dr Reddy’s Laboratories

Eisai

Eon Labs Manufacturing

General Motors

Genpharm Inc

Genzyme Corp

GlaxoSmithKline

Ilyang Pharmaceutical Company

Impax Laboratories

Ivax Pharmaceuticals

Janssen Pharmaceutica

Johnson & Johnson

KUDCo

Kyowa Hakko Kogyo

Laboratorios Davur

Lek Pharmaceutical and Chemical Company

Lek Services USA

Merck & Co

Merck KGaA

Motorola

Mylan Pharmaceuticals

Novartis

NPS Pharmaceuticals

Otsuka America Pharmaceutical

Pain Therapeutics

Par Pharma

Pfizer

Proctor & Gamble

Progenics Pharmaceuticals

Ranbaxy Laboratories

Roche

Salix Pharmaceuticals

Sandoz

Sankyo

Sanofi-Aventis

Santarus

Schering AG

Schwarz Pharma

Shire US Inc

Solvay Pharmaceuticals

Sucampo Pharmaceuticals

Sumitomo Pharmaceuticals Co

Takeda Chemical Industries

Takeda Pharmaceutical

TAP Pharmaceutical Products

Teva Pharmaceuticals

Teva USA

Torpharm

UCB Pharma

Wal-Mart

Wyeth

Zenith Goldline Pharmaceuticals

Format: CD-ROM

Publication Date: January 2006
Table of Contents

Price
Single User Licence $3598.00
Department Licence 5 Users $7198.00
Company-wide Intranet Licence $10798.00